Dublin, April 07, 2026 (GLOBE NEWSWIRE) — The “Molecular Tumor Board Solutions Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
The molecular tumor board solutions market is experiencing robust growth, projected to expand from $1.53 billion in 2025 to $1.74 billion in 2026 at a CAGR of 13.7%. This growth is driven by the expansion of precision oncology programs, the rise of genomic sequencing data, multidisciplinary cancer care team development, and increasing use of clinical decision support tools. The market is further anticipated to reach $2.87 billion by 2030, fueled by investments in personalized cancer treatment, demand for molecularly guided therapies, and the integration of AI-driven oncology analytics.
Noteworthy trends include the increased use of AI-assisted variant interpretation, expanded cloud-based tumor board platforms, and enhanced personalized oncology workflows. The growing incidence of cancer is a significant factor propelling market growth, underscored by the World Health Organization’s projection of 35 million new cases by 2050. Molecular tumor board solutions are vital in integrating genomic data and expert knowledge for personalized cancer treatment.
Leading companies in the sector are innovating with solutions like molecular profiling tests to enhance diagnostic accuracy. For instance, Guardant Health Inc. launched the Guardant360 Tissue in April 2025, an advanced profiling test that encompasses multiomic analysis for superior cancer treatment insights. This test, part of the Guardant Infinity smart liquid biopsy platform, is Medicare-covered for eligible patients and promises expedited results delivery, supporting therapies like PARP inhibitors and immunotherapies.
Industry activity includes strategic acquisitions, such as Labcorp Holdings Inc.’s $237.5 million purchase of BioReference Health LLC in September 2024, aiming to expand lab service networks and enhance access to genomic testing. Prominent market players comprise F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Illumina Inc., and many more.
North America dominated the market share in 2025, while Asia-Pacific is set to be the fastest-growing region in the future. Regions covered in the market analysis include Asia-Pacific, South East Asia, Western and Eastern Europe, North America, South America, the Middle East, and Africa, with countries like Australia, Brazil, and China among others.
Report Scope
- Acquire a comprehensive global perspective with insights covering 16 diverse geographies.
- Understand the influence of macroeconomic elements such as geopolitical conflicts, trade policies, inflation, and interest rate shifts.
- Formulate regional and country-specific strategies grounded in local data analysis.
- Identify key growth segments for potential investment opportunities.
- Leverage forecast data and emerging trends to gain a competitive edge.
- Profile consumer behavior with end-user analysis.
- Benchmark against major competitors through market share insights, innovation metrics, and brand strength analysis.
- Evaluate market potential using total addressable market (TAM) analytics and market attractiveness scoring.
- Utilize reliable data for internal and external presentations, complete with an Excel data sheet for easy extraction and analysis.
- Receive updates with the latest data, formatted within an Excel dashboard for streamlined data interaction.
Markets Covered:
- Component: Software; Services
- Deployment Mode: On-Premises; Cloud-Based
- Application: Clinical Decision Support; Genomic Data Interpretation; Patient Management; Other Applications
- End-User: Hospitals; Cancer Centers; Research Institutes; Other End-Users
Subsegments:
- Software: Clinical Decision Support; Data Analytics; Reporting And Visualization; Integration Platforms
- Services: Consulting; Implementation; Training And Support; Maintenance And Upgrades
Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Regions: Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, and expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, competitor market share, market segments.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $1.74 Billion |
| Forecasted Market Value (USD) by 2030 | $2.87 Billion |
| Compound Annual Growth Rate | 13.4% |
| Regions Covered | Global |
The companies featured in this Molecular Tumor Board Solutions market report include:
- F. Hoffmann-La Roche Ltd
- Thermo Fisher Scientific Inc.
- Siemens Healthineers AG
- Koninklijke Philips N.V.
- Illumina Inc.
- Novogene Co. Ltd.
- QIAGEN N.V.
- Myriad Genetics Inc.
- BGI Genomics Co. Ltd.
- Guardant Health Inc.
- Caris Life Sciences Inc.
- Mayo Clinic Laboratories
- Sectra AB
- GenomOncology LLC
- MedGenome Labs Ltd.
- Burning Rock Biotech Limited
- NantHealth Inc.
- SOPHiA GENETICS SA
- Variantyx Inc.
- Baylor Genetics
- Molecular Health GmbH
- PierianDx Inc.
- Oncompass Medicine
- CureMatch Inc.
For more information about this report visit https://www.researchandmarkets.com/r/9s9em6
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Molecular Tumor Board Solutions Market
